Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 2364 clinical trials
featured
GRAVITAS-301: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids for the Treatment of First-Line Acute Graft-Versus-Host Disease

GRAVITAS-301: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids for the Treatment of First-Line Acute Graft-Versus-Host Disease

graft-versus-host disease
  • 1462 views
  • 08 Dec, 2020
  • 11 locations
featured
A Study to Evaluate the Efficacy, Safety and Tolerability of Combinations Study medication and Mirabegron Compared to Study medication and Mirabegron Monotherapy in the Treatment of Overactive Bladder

A Study to Evaluate the Efficacy, Safety and Tolerability of Combinations Study medication and Mirabegron Compared to Study medication and Mirabegron Monotherapy in the Treatment of Overactive

  • 180 views
  • 23 Nov, 2020
  • 1 location
featured
A Phase 1/1b Study of Sitravatinib in Combination with Nivolumab and Ipilimumab in Patients with Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid Malignancies

malignancies that have shown favorable responses to NIVO/IPI combinations in previous clinical trials. Combining sitravatinib and NIVO/IPI is predicted to have complementary effects in triggering a tumor

systemic therapy
nivolumab
tyrosine
carcinoma
ipilimumab
  • 27 views
  • 15 Sep, 2020
  • 1 location
featured
A Randomized Phase II Study of Perioperative mFOLFIRINOX versus Gemcitabine/nab-Paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma

A Randomized Phase II Study of Perioperative mFOLFIRINOX versus Gemcitabine/nab-Paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma

adenocarcinoma
gemcitabine
paclitaxel
pancreatic adenocarcinoma
  • 178 views
  • 23 Nov, 2020
  • 1 location
featured
SYNERGY

SYNERGY

  • 86 views
  • 08 Nov, 2020
  • 1 location
featured
Alliance/NCCTG N1048: A Phase II/III Trial of Neoadjuvant FOLFOX, With Selective Use of Combined Modality Chemoradiation Versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection With Total Mesorectal Excision

Alliance/NCCTG N1048: A Phase II/III Trial of Neoadjuvant FOLFOX, With Selective Use of Combined Modality Chemoradiation Versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection With Total Mesorectal Excision

  • 114 views
  • 08 Nov, 2020
  • 1 location
featured
AALL0434: Combination Chemotherapy in Treating Young Patients with Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia

AALL0434: Combination Chemotherapy in Treating Young Patients with Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia

  • 170 views
  • 08 Nov, 2020
  • 1 location
featured
A Double-Blind, Randomized controlled study of Etanercept and Methotrexate in combination or as Monotherapy in subjects with Psoriatic Arthritis

A Double-Blind, Randomized controlled study of Etanercept and Methotrexate in combination or as Monotherapy in subjects with Psoriatic Arthritis

  • 396 views
  • 23 Nov, 2020
  • 1 location
featured
A Study of INCB039110 in Combination With Ibrutinib in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

A Study of INCB039110 in Combination With Ibrutinib in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

  • 180 views
  • 23 Nov, 2020
  • 1 location
featured
Phase III, randomized, double-blind, active-controlled, parallel-group study, comparing the efficacy, safety and tolerability of the fixed dose combination of FF/UMEC/VI with the fixed dose dual combination of FF/VI, administered once-daily via a dry powder inhaler in subjects with inadequately controlled ASTHMA.

Phase III, randomized, double-blind, active-controlled, parallel-group study, comparing the efficacy, safety and tolerability of the fixed dose combination of FF/UMEC/VI with the fixed dose dual combination of FF/VI, administered once-daily via a dry powder inhaler in subjects with inadequately controlled ASTHMA.

  • 430 views
  • 23 Nov, 2020
  • 1 location